生物制剂的纳米胶囊化:提高稳定性和改善肠道健康的可行性。

IF 5.5 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Pedro Brivaldo Viana da Silva, Thiécla Katiane Osvaldt Rosales, João Paulo Fabi
{"title":"生物制剂的纳米胶囊化:提高稳定性和改善肠道健康的可行性。","authors":"Pedro Brivaldo Viana da Silva, Thiécla Katiane Osvaldt Rosales, João Paulo Fabi","doi":"10.3390/pharmaceutics17091180","DOIUrl":null,"url":null,"abstract":"<p><p>The human gastrointestinal tract contains a complex and diverse community of microorganisms, referred to as the gut microbiota. Due to their close proximity to human cells, these microorganisms play a crucial role in maintaining the host's health, influencing various metabolic processes, and providing protection against potentially harmful agents and pathogens. The disruption in this microbial ecosystem, known as dysbiosis, is associated with inflammatory and metabolic diseases, as well as certain types of cancer. Strategies to modulate the microbiota toward a state of homeostasis through the use of \"biotics\" (probiotics, prebiotics, synbiotics, and postbiotics) have increased. However, challenges such as low stability, loss of microbial viability, and difficulties in delivery to the intestine significantly decrease the progress of their clinical and nutritional applications. Microencapsulation and nanoencapsulation technologies offer potential solutions to enhance the stability, bioavailability, and controlled release of microorganisms and/or bioactive compounds within the gastrointestinal tract. Considering these aspects, this review provides a comprehensive overview of recent advances in nanoencapsulation techniques for biotics, highlighting their mechanisms of action, potential health benefits, and applications in functional foods and targeted therapies. Furthermore, it addresses existing limitations, evaluates feasibility, and discusses the future potential of these technologies in promoting gut health and disease prevention. Further research, especially through clinical studies, is mandatory to verify the safety and effectiveness of nanoencapsulated biotics and to obtain regulatory approval.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"17 9","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473147/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.\",\"authors\":\"Pedro Brivaldo Viana da Silva, Thiécla Katiane Osvaldt Rosales, João Paulo Fabi\",\"doi\":\"10.3390/pharmaceutics17091180\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The human gastrointestinal tract contains a complex and diverse community of microorganisms, referred to as the gut microbiota. Due to their close proximity to human cells, these microorganisms play a crucial role in maintaining the host's health, influencing various metabolic processes, and providing protection against potentially harmful agents and pathogens. The disruption in this microbial ecosystem, known as dysbiosis, is associated with inflammatory and metabolic diseases, as well as certain types of cancer. Strategies to modulate the microbiota toward a state of homeostasis through the use of \\\"biotics\\\" (probiotics, prebiotics, synbiotics, and postbiotics) have increased. However, challenges such as low stability, loss of microbial viability, and difficulties in delivery to the intestine significantly decrease the progress of their clinical and nutritional applications. Microencapsulation and nanoencapsulation technologies offer potential solutions to enhance the stability, bioavailability, and controlled release of microorganisms and/or bioactive compounds within the gastrointestinal tract. Considering these aspects, this review provides a comprehensive overview of recent advances in nanoencapsulation techniques for biotics, highlighting their mechanisms of action, potential health benefits, and applications in functional foods and targeted therapies. Furthermore, it addresses existing limitations, evaluates feasibility, and discusses the future potential of these technologies in promoting gut health and disease prevention. Further research, especially through clinical studies, is mandatory to verify the safety and effectiveness of nanoencapsulated biotics and to obtain regulatory approval.</p>\",\"PeriodicalId\":19894,\"journal\":{\"name\":\"Pharmaceutics\",\"volume\":\"17 9\",\"pages\":\"\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473147/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/pharmaceutics17091180\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics17091180","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

人体胃肠道包含一个复杂而多样的微生物群落,称为肠道微生物群。由于它们与人体细胞非常接近,这些微生物在维持宿主健康,影响各种代谢过程以及提供对潜在有害物质和病原体的保护方面发挥着至关重要的作用。这种微生物生态系统的破坏被称为生态失调,与炎症和代谢疾病以及某些类型的癌症有关。通过使用“益生菌”(益生菌、益生元、合成菌和后益生菌)将微生物群调节到稳态状态的策略有所增加。然而,诸如低稳定性、微生物活力丧失和肠道输送困难等挑战大大降低了其临床和营养应用的进展。微胶囊化和纳米胶囊化技术为提高微生物和/或生物活性化合物在胃肠道内的稳定性、生物利用度和控制释放提供了潜在的解决方案。考虑到这些方面,本文综述了生物纳米胶囊技术的最新进展,重点介绍了它们的作用机制、潜在的健康益处以及在功能食品和靶向治疗中的应用。此外,它解决了现有的局限性,评估了可行性,并讨论了这些技术在促进肠道健康和疾病预防方面的未来潜力。进一步的研究,特别是通过临床研究,必须验证纳米胶囊生物制剂的安全性和有效性,并获得监管部门的批准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.

Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.

Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.

Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.

The human gastrointestinal tract contains a complex and diverse community of microorganisms, referred to as the gut microbiota. Due to their close proximity to human cells, these microorganisms play a crucial role in maintaining the host's health, influencing various metabolic processes, and providing protection against potentially harmful agents and pathogens. The disruption in this microbial ecosystem, known as dysbiosis, is associated with inflammatory and metabolic diseases, as well as certain types of cancer. Strategies to modulate the microbiota toward a state of homeostasis through the use of "biotics" (probiotics, prebiotics, synbiotics, and postbiotics) have increased. However, challenges such as low stability, loss of microbial viability, and difficulties in delivery to the intestine significantly decrease the progress of their clinical and nutritional applications. Microencapsulation and nanoencapsulation technologies offer potential solutions to enhance the stability, bioavailability, and controlled release of microorganisms and/or bioactive compounds within the gastrointestinal tract. Considering these aspects, this review provides a comprehensive overview of recent advances in nanoencapsulation techniques for biotics, highlighting their mechanisms of action, potential health benefits, and applications in functional foods and targeted therapies. Furthermore, it addresses existing limitations, evaluates feasibility, and discusses the future potential of these technologies in promoting gut health and disease prevention. Further research, especially through clinical studies, is mandatory to verify the safety and effectiveness of nanoencapsulated biotics and to obtain regulatory approval.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmaceutics
Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.90
自引率
11.10%
发文量
2379
审稿时长
16.41 days
期刊介绍: Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications,  and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信